RTP Mobile Logo
Soft Tissue Sarcoma Update: Medical Edition, Issue 1, 2017
Released April 2017

Featuring interviews with Drs Brian A Van Tine and Seth M Pollack. (Audio Content)

CE Disclosures and Faculty Information

    Sarcomas constitute a heterogeneous group of rare solid tumors of mesenchymal origin with distinct clinical and pathologic features. More than 50 different subtypes of soft tissue sarcoma (STS) exist in a variety of anatomic locations. Because of this heterogeneity and the historical lack of effective systemic therapeutic options, clinical decision-making for patients with STS has often been made on a case-by-case basis. However, significant research strides made during the past few years have led to the approval of new treatments for the disease in addition to the identification of a number of other novel agents demonstrating great promise. Featuring information on the latest clinical and research developments along with expert perspectives, this CME activity is designed to assist medical oncologists with the formulation of up-to-date clinical management strategies for the care of patients with STS.


    • Recognize the importance of multidisciplinary collaboration in the diagnosis and management of STS, and use this information to guide therapeutic decision-making.
    • Appreciate the recent FDA approvals of trabectedin, eribulin and olaratumab, and discern how these agents can be integrated into the clinical algorithm for patients with STS.
    • Appraise available efficacy data with pazopanib for patients with advanced STS, and assess how this agent can be optimally incorporated into current clinical practice.
    • Evaluate the role of neoadjuvant and adjuvant chemotherapy in the clinical management of STS.
    • Explore emerging data with immune checkpoint inhibitors, and use this information to counsel appropriate individuals regarding potential participation in ongoing trials.

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and Research To Practice. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians. CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity contains an audio component.

    CME credit is no longer available for this issue

    It is the policy of Research To Practice and Penn State College of Medicine to ensure balance, independence, objectivity and scientific rigor in all their educational programs. All faculty, planners and managers participating in this activity are required to disclose any relevant financial relationship(s) they (or spouse/partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interest. Research To Practice and Penn State College of Medicine ensured that any conflicts of interest were resolved before the educational activity occurred.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Van TineAdvisory Committee: Caris Life Sciences, EMD Serono Inc, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly, Novartis; Contracted Research: Eisai Inc, Merck, Pfizer Inc; Paid Research: Eisai Inc, Merck; Speakers Bureau: Caris Life Sciences, GlaxoSmithKline, Novartis. Dr PollackAdvisory Committee: Amgen Inc, Lilly, Nektar; Consulting Agreements: Amgen Inc, Eisai Inc, Lilly; Contracted Research: EMD Serono Inc, Immune Design, Lilly, Merck.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc,, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    PENN STATE COLLEGE OF MEDICINE — Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice and Penn State College of Medicine do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Eisai Inc, Janssen Biotech Inc and Lilly. 

    Release date: April 20, 2017
    Expiration date: April 20, 2018

Acknowledge and close

Listen to audio:
Soft Tissue Sarcoma Update: Medical Edition, Issue 1, 2017
Released April 2017

Featuring interviews with Drs Brian A Van Tine and Seth M Pollack. (Audio Content)

Read print: